Simulating tumor complexity: 3D pancreatic tumor spheroid model for improved drug screening

Area of Science:

• Oncology
• Drug Discovery
• Biotechnology

Background:

• Traditional 2D cell cultures and animal models present limitations in preclinical drug screening due to physiological differences.
• High failure rates in clinical trials, particularly in oncology, stem from inadequate preclinical models that do not reflect human tumor complexity.

Purpose of the Study:

• To develop and validate a 3D pancreatic tumor spheroid model for more accurate preclinical drug evaluation.
• To assess the utility of this 3D model in predicting therapeutic responses, tumor microenvironment interactions, and biomarker expression.

Main Methods:

• Established 3D monocellular and multicellular pancreatic tumor spheroids using PANC-1 and PANC04.03 cell lines.
• Evaluated drug effects on cellular viability, spheroid shrinkage, and pre-vascularization.
• Assessed gene expression of cancer stem cell (CSC), epithelial-mesenchymal transition (EMT), and apoptotic markers via RT-qPCR.

Main Results:

• 3D spheroids demonstrated a more relevant platform for drug potency evaluation compared to 2D cultures.
• Significant differences in drug response and biomarker expression were observed between 2D and 3D models.
• The KRAS-G12D inhibitor MRTX1133 showed enhanced drug response profiles in 3D spheroids compared to 2D cultures.

Conclusions:

• 3D multicellular tumor models are crucial for comprehensive drug evaluation, offering a more physiologically relevant platform than 2D cultures.
• This 3D model has the potential to bridge the gap between in vitro preclinical studies and clinical outcomes in oncology drug development.